Literature DB >> 15729688

The partial retro-inverso modification: a road traveled together.

Michael Chorev1.   

Abstract

In the mid-1970s, Dr. Murray Goodman was interested in a reversed peptide bond as a surrogate to understand the functional role of the amide bond in aspartame, a dipeptide sweetener. Very soon, realizing the breath and potential of this modification, Murray expanded this activity into a full program and I was fortunate to be part of it. Together we formulated new concepts such as the partially modified retro-inverso and end-group modified retro-inverso transformations, tested hypotheses, generated novel nomenclature, developed synthetic routes, characterized the preferred conformations of the unique building blocks employed in this modification, the gem-diaminoalkyl and the C2-substituted malonyl residues, and studied the biological activity of retro-inverso isomers of bioactive peptides. In the early 1980s several laboratories initiated extensive research targeted at the retro-inverso modification. The revival of this field led to new applications, new methods of synthesis, and new insights on the conformational and topological properties of the retro-inverso modification. Among the fields that embraced the retro-inverso concept were immunology as pertains to subjects such as synthetic vaccines, immunomodulators, and diagnostic tools, and drug delivery field as pertains to targeted and nontargeted cell permeation vectors loaded with bioactive cargo. Doctor Murray Goodman's sudden death leaves behind not only family, friends, and colleagues, but also an impressive record of scientific achievements among which is the revival of the modern era of the retro-inverso transformation. Murray's numerous contributions, excellent leadership, enthusiastic promotion, and outstanding teachings in this field will carry and illuminate his memory far into the future. Copyright 2005 Wiley Periodicals, Inc

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15729688     DOI: 10.1002/bip.20219

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  16 in total

1.  A multicomponent approach to the synthesis of 1,3-dicarbonylic compounds.

Authors:  Ana G Neo; Rosa M Carrillo; Jose Delgado; Stefano Marcaccini; Carlos F Marcos
Journal:  Mol Divers       Date:  2010-09-03       Impact factor: 2.943

Review 2.  Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.

Authors:  Pravin T P Kaumaya; Kevin Chu Foy
Journal:  Future Oncol       Date:  2012-08       Impact factor: 3.404

3.  From combinatorial peptide selection to drug prototype (I): targeting the vascular endothelial growth factor receptor pathway.

Authors:  Ricardo J Giordano; Marina Cardó-Vila; Ahmad Salameh; Cristiane D Anobom; Benjamin D Zeitlin; David H Hawke; Ana P Valente; Fábio C L Almeida; Jacques E Nör; Richard L Sidman; Renata Pasqualini; Wadih Arap
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-26       Impact factor: 11.205

4.  Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo.

Authors:  Kevin C Foy; Zhenzhen Liu; Gary Phillips; Megan Miller; Pravin T P Kaumaya
Journal:  J Biol Chem       Date:  2011-02-16       Impact factor: 5.157

5.  Assessing the Role of a Malonamide Linker in the Design of Potent Dual Inhibitors of Factor Xa and Cholinesterases.

Authors:  Rosa Purgatorio; Nicola Gambacorta; Francesco Samarelli; Gianfranco Lopopolo; Modesto de Candia; Marco Catto; Orazio Nicolotti; Cosimo D Altomare
Journal:  Molecules       Date:  2022-07-02       Impact factor: 4.927

6.  Novel peptide isomer strategy for stable inhibition of catecholamine release: application to hypertension.

Authors:  Nilima Biswas; Jiaur Gayen; Manjula Mahata; Ying Su; Sushil K Mahata; Daniel T O'Connor
Journal:  Hypertension       Date:  2012-11-05       Impact factor: 10.190

7.  An APP inhibitory domain containing the Flemish mutation residue modulates gamma-secretase activity for Abeta production.

Authors:  Yuan Tian; Bhramdeo Bassit; Deming Chau; Yue-Ming Li
Journal:  Nat Struct Mol Biol       Date:  2010-01-10       Impact factor: 15.369

8.  Whole-body PET tracking of a d-dodecapeptide and its radiotheranostic potential for PD-L1 overexpressing tumors.

Authors:  Kuan Hu; Wenyu Wu; Lin Xie; Hao Geng; Yiding Zhang; Masayuki Hanyu; Lulu Zhang; Yinghuan Liu; Kotaro Nagatsu; Hisashi Suzuki; Jialin Guo; Yundong Wu; Zigang Li; Feng Wang; Mingrong Zhang
Journal:  Acta Pharm Sin B       Date:  2021-09-22       Impact factor: 14.903

9.  Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer.

Authors:  Kevin C Foy; Megan J Miller; Nicanor Moldovan; Tatjana Bozanovic; William E Carson; Pravin T P Kaumaya
Journal:  Oncoimmunology       Date:  2012-10-01       Impact factor: 8.110

Review 10.  Motif mediated protein-protein interactions as drug targets.

Authors:  Carles Corbi-Verge; Philip M Kim
Journal:  Cell Commun Signal       Date:  2016-03-02       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.